Summary
Vertex Pharmaceuticals Incorporated (VRTX) announced on May 6, 2004, a significant one-time grant of restricted stock to its senior managers and executives at the Vice-President level and above. This strategic move, developed in consultation with an external compensation firm and approved by the Board of Directors, aims to bolster executive retention during a crucial growth phase for the company. The structure of the award is tied to individual roles and salaries, aligning executive interests directly with the long-term success of Vertex. The restricted stock is subject to a vesting schedule, with 50% vesting three years after the grant date (May 6, 2007) and the remaining 50% vesting on May 6, 2009. Notably, the second tranche may vest earlier if the company achieves profitability, as determined by the Board. This compensation strategy is designed to incentivize key personnel to remain with Vertex and foster a strong connection between executive compensation and shareholder value.
Key Highlights
- 1Vertex Pharmaceuticals issued a one-time grant of restricted stock to senior management (VP level and above).
- 2The grant aims to retain key executives during a critical development and growth period.
- 3Awards are customized based on individual title, responsibilities, and base salary.
- 4The restricted stock vests in two tranches: 50% on May 6, 2007, and 50% on May 6, 2009.
- 5Early vesting of the second tranche is possible if the company becomes profitable, as determined by the Board.
- 6This initiative aligns executive compensation with stockholder return and encourages long-term commitment.
- 7The compensation structure was designed with input from an outside compensation consulting group and approved by the Board.